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Abstract
Abstract
The detection of Copy Number Variants (CNVs) has been gradually introduced into routine
diagnostics over the last 15 years and has been described as an important source of pathogenic
variants in rare diseases. Despite this, the clinical interpretation remains a challenge and our
understanding of the functional impact of these alterations on biological processes is limited,
which hinder the diagnosis and the discovery of new therapies. One main reason of these lim-
itations is the lack of integrated data and resources that efficiently assess causative genes with
the patient phenotype. To address this challenge, we present CNVxplorer, a user-friendly web
application for the interpretation of CNVs. For any given genomic interval, CNVxplorer allows
to assess genes mapped in the region, through the integration of human genetics databases of
clinical interest, experiment-based information on tissue expression, biomedical ontologies, scien-
tific literature, regulatory regions, functional annotation and the option to perform enrichment
analysis. All the results are arranged into a concise output and an automated report can be
downloadable. The app provides a highly dynamic and user-friendly interface and the website
will be publicly available.
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1
Introduction
Rare diseases affect more than 300 million people worldwide. There are about 6,000-8,000 rare
diseases and the majority of these diseases affect children (50-75%) [1]. These disorders are
responsible for 35% of deaths in the first year of life in United States and are a significant cause
of paediatric hospital admissions [2], where two-third are serious and disabling and half are life-
limiting [3]. In spite of the scientific advances during the last years, the clinical outcome has
slightly improved for the majority of these patients since major challenges need to be yet solved:
1.1 Challenges for drug development
The development of new therapies is hindered by the reduced commercial viability due to the
low prevalence of rare diseases in the population. As a way to revert this reality, regulatory
and public entities have provided incentives and a growing public investment to enhance the
development of drugs for rare diseases. Initiatives such as the Orphan Drug Act (ODA) in
United States or the Regulation on Orphan Medicinal Products in the European Union (EU) in
2000 have been successful in the development of new orphan drugs. For instance, before this, few
drugs had been launched to the market, but since its implementation, the FDA has approved
more than 600 orphan drugs [4].
Nowadays, it has been estimated that only 6% of rare disease currently have available treat-
ment, of which less that 1% are curative [5], leaving a large majority of patients still awaiting
a therapy. Considering the actual pace of research and development, most clinically tractable
rare disease will not have new treatments for a long time.
1.2 Challenges for clinical diagnostic
For children with a rare disease, an accurate diagnosis is crucial in order to provide advice, pos-
sible therapies and to assess the potential risk to existing family members of future generations.
Public initiatives such as the International Rare Diseases Research Consortium (IRDiRC) set
the goal for 2017-2027 of “enable all people living with a rare disease to receive an accurate
diagnosis, care and available therapy within of coming to medical attention“ [6].
1
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Figure 2.
Figure 1. Spending on orphan drugs in the United States. US dollars. Source: IQVIA National
Sales Perspectives, Jan 2018; FDA Orphan Drug Database. Report: Orphan Drugs in the United
States Growth Trends in Rare Disease Treatments, IQVIA Institute for Human Data Science,
Oct 2018.
In spite of this, achieving precision diagnosis for each individual remains a difficult challenge
due to two main aspects:
• Genetic variability. The spectrum of genetic variants is broad and heterogeneous, from
single nucleotide variants (SNVs) to structural variants (SV) and altered number of chro-
mosomes (aneuploidy) or genome (diploid/triploid mosaicism). Another important source
of variability is cis-acting variants that may alter regulation for a unique allele through a
change to promoter/enhancer regions (transcription factor binding sites), or even through
3’ UTR mutations that affect mRNA stability. Besides, these variants can affect only one
allelic copy (heterocygotes) or both (homocygotes).
• Phenotypic variability. Due to the high number of rare diseases, clinical features of
diseases tend to overlap. In addition, patients with the same disease can present a different
phenotype as a result of incomplete penetrance or expressivity.
Two disorders that illustrate this heterogeneity are described below:
• Cystic fibrosis. Monogenic disorder caused by mutations in the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene. Despite being a single-gene disorder, there are
described around 150 disease causing mutations which are classified in 6 different classes
according to the altered molecular function. The genetic variability has generated a broad
range of disease severity. Therapeutic options have focused on preventing and treating
complications of the disease, until recently, with a better understanding of the genetic
abnormalities, new compounds are already being assessed in clinical trials [7].
• Bardet–Biedl syndrome (BBS). Autosomal recessive disorder caused by variants in
over 20 genes with indistinguishable clinical presentations [8].
All this heterogeneity adds up to some other aspects:
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• Due to the low prevalence of these diseases, in most cases, the cohort studies comprise a
small number of patients which reduce the statistical power to find causal variants.
• The influence of environmental factors that are difficult to identify and measure.
• Patients with monogenic diseases can harbour apart variants at loci (e.g. non-coding) that
can alter the proper clinical features of the disease.
To sum up, the heterogeneity of rare diseases hinder the assessment of the association
genotype-phenotype and therefore the development of new drugs and an accurate diagnostic
of these patients.
1.3 Gene discovery, a key step to address these challenges
Genetic cause of at least one-third of rare diseases has yet to be discovered [3]. Development
of new diagnostic tools and new drugs certainly depend on the identification of causal genetic
drivers and our own understanding of the underlying biological mechanisms.
In this thesis, we focus on copy number variants (CNVs), a class of structural variants which
increases or decreases the DNA content through deletions or duplications respectively. CNVs are
known to contribute substantially to phenotypic diversity and disease. They have been associated
with conditions such as autism [9], schizophrenia [10], Crohn’s disease [11], rheumatoid arthritis
[11], or type 1 diabetes [11]. In addition, it is a major cause of many developmental disorders
including intellectual disability and congenital anomalies [12].
The interpretation of CNVs relies heavily on frequency information from healthy control
cohorts and databases with previously reported clinically relevant CNVs. Other factors, such
as length, location (interstitial/centromeric/repeat regions) and gene content of the CNV [13]
are assess. Since the size of a CNV is directly related with the number of genes affected, the
likeliness of pathogenicity increases accordingly with the size of the CNV.
Despite of its relevance, interpreting the pathogenicity of CNVs remain challenging and
clinical geneticists need to discriminate arbitrarily pathogenic or high-risk from benign variants
in patients. This process is laborious since the clinicians have to curate manually different
databases. Even though the CNVs are correctly associated with the clinical features of the
patient, the causal variant can remain unsolved since numerous genes can be mapped in the
same CNV. Besides, there is not a systematic protocol to interpret these variants, which limit
the reproducibility and traceability of the clinical decisions.
Recent efforts have been made to improve the interpretation of CNVs. In addition, some tools
have been developed, such as Moon, a commercial software developed by the company Diploid.
It consists of a cloud-based software which prioritize variants associated to the symptoms of the
patient and displays a variant ranking. Despite the possible advantages, it works as a black-box,
since the user can not explore the variables or the parameters used and therefore, it takes away
the opportunity to interpret the results by a professional. Other tools, such as MARRVEL [14]
or VarCards [15] focus on SNVs and solely permit to analyze genes individually without taking
into account the possible aggregated effect of multiple genes and increase the analysis time. As
a consequence, clinical and research laboratories which need to interpret CNVs do not have the
chance to work efficiently due to the lack of tools oriented to this type of mutations.
Here, we present CNVxplorer, a web tool which allows the interpretation of CNVs in a rapid
way through the integration of multiples databases with gene-level information, clinical relevance
data, regulatory regions and a set of downstream analysis. The design of the tool is user-friendly
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and allow to download an automated report with results in order to improve the traceability
required in a clinical environment.
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2
Results
2.1 CNVxplorer integrates data from human databases
CNVxplorer builds upon and complement existing tools by integrating genic intolerance scores,
dosage effect, tissue-specific expression, disease-associated genes, downstream analysis and other
information into a user-friendly web application. To analyze a CNV, CNVxplorer allows entry
of a genomic interval or a chromosomal band. First, the app displays a general overview of
the genes located in the region with broadly used genic intolerance scores (pLI, RVIS, ncRVIS,
ncGERP) and identifies those genes located in human genetic databases (OMIM, FDA, GWAS,
ClinGen, DECIPHER, ClinVar). Through this information, the user has the option to filter out
those genes that not satisfy one or multiples criteria (e.g. genes with pLI >= 0.9 and found in
OMIM). These filtered genes will be used along the rest of analysis, but the user can modify
any filter and update this list during the same user session. Second, CNVxplorer displays if
the region chosen by the user overlaps with any CNV from DECIPHER (CNVs from patients
with developmental disorders) or gnomAD/DGV (CNVs from healthy population). Besides,
CNVxplorer identifies if the input region is located in an inaccurate genomic annotation regions,
such as segmental duplications or low-mappability regions.
2.2 CNVxplorer allows to explore the regulatory architecture
CNVxplorer allows to visualize regulatory regions located in the CNV, such as enhancers or
long noncoding RNAs (lncRNAs). In addition, it displays TADs boundaries that are disrupted.
Since the enhancers and lncRNAs are characterized by a high level of redundancy, many variants
that affect these regulatory regions do not have a functional impact [16] [17]. As a consequence,
CNVxplorer displays for each enhancer two scores broadly used in the identification of conserved
regions in the genome:
• Conservation inter-species using PhastCon [18] with three different multiple alignments:
vertebrates, mammals and primates.
• Conservation intra-species using the gnomAD database [19] of 15,708 genomes from human
sequencing studies. To that end, we calculated the ratio of the number of observed variants
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Figure 2. Data resources used by CNVxplorer. Blue color represents local data and green color
represents information obtained through API queries.
and the sum of expected variants per each nucleotide in the region (see Material and
Methods).
In addition, the user can filter the list of enhancers based on these scores and has the option
to include the target genes, that are not located in the CNV, in the analysis.
2.3 CNVxplorer eases functional analysis of gene groups
CNVxplorer allows the annotation of genes based on Gene Ontology (GO), where the user can
specify the GO level and the ontology source. In addition, it can perform functional enrichment
analysis from multiples ontologies: biological process, molecular function or cellular component
(Gene Ontology), pathways (KEGG, REACTOME) and diseases (Disease Ontology). Besides,
the user can specify the p-value cutoff of each analysis. Lastly, these results are displayed through
plots and table format.
2.4 CNVxplorer facilitates the clinical interpretation of CNVs
In order to enhance the clinical interpretation between the genes of the region affected and the
patient’s phenotype, CNVxplorer offers three different approaches:
First, CNVxplorer summarizes human expression data per gene from two sources. For gene
expression data, the source is GTEx, which provides quantitative expression data of each gene
in 53 human tissues. For protein levels, the source is the Protein Atlas database.
The information about gene-level expression across tissues brings the possibility to assess
genes expressed in tissues that are associated with the affected organ(s) in the patient.
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Second, the user can select the phenotype terms observed in the patient. CNVxplorer will
display only the list of genes located in the CNV that have been associated previously with these
clinical features.
Third, CNVxplorer displays the articles from PubMed that has been associated before with
that genomic region. Every displayed article includes the title, date of publication, number of
cites and a link to the original manuscript.
Here, we provide an example of how CNVxplorer displays information useful for gene pri-
oritization. We describe a specific case for which CNVxplorer can be used to facilitate manual
analysis of genes located in a CNV.
Zhu et al. [20] recently successfully performed the identification of six CNV regions associated
with congenital diaphragmatic hernia (CDH). This disorder is characterized by a developmental
discontinuity of the diaphragm and hypoplasia of the lungs.
As an example of how CNVxplorer can help to interpret CNVs, we investigate the gene
content of one of the CNV region described by the authors (chr17:34813719–36278623). To
emphasize the flexibility of CNVxplorer, we use two different approaches (Figure 3) to interpret
15 genes mapped in this region:
Approach 1. The first step is to filter genes based on pLI score (pLI >= 0.9). Of the 15
genes, 4 (ACACA, GGNBP2, HNF1B and SYNRG) have a pLI score above or equal to 0.9,
indicating a high intolerance of loss-of-function variants. Based on functional analysis (Gene
Ontology - Biological Process), we detect 2 genes (GGNBP2, HNF1B) enriched significantly
(p-value < 0.05) for the terms: utero embryonic development (GO:0001701) and embryonic
organ development (GO:0048568). To corroborate the relevance of these two genes, we compare
it with clinical features of patients with CDH. We found one gene (HNF1B) associated with
Pancreatic hypoplasia (HP:0002594) but not with Lungs hypoplasia (HP:0002089). Since CDH is
characterized by extradiaphragmatic associated anomalies (46% of the cases [21], the disruption
of this gene could explain partially the phenotypic heterogeneity of this disease.
Approach 2. In this case, we decided to use HI score (HI <= 10). Of the 15 genes, 5
(AATF, ACACA, HNF1B, LHX1, TADA2A) have a HI score below or equal to 10, indicating
a high probability of being a haploinsufficient gene. Based on functional analysis (Gene Ontol-
ogy - Biological Process), we detect 2 genes (HNF1B, LHX1) enriched significantly (p-value <
0.05) for the terms: regulation of gastrulation (GO:0010470) and embryonic organ development
(GO:0048568). We assess these two genes with the current biomedical literature and both genes
have been described before playing a role in congenital disorders. In the case of HNF1B in
Duodenal atresia (PMID: 25256560) and developmental kidney disease (PMID:27234567) and
LHX1 in Müllerian aplasia (PMID:23954021, PMID:22740494).
These two approaches reflect the flexibility of the application to analyse a genomic interval,
since the user has the opportunity to explore different parameters to filter genes. For instance,
in the first approach, the gene LHX1 is filtered out due to a low pLI score (0.03). Thanks to a
second approach, using HI score as the parameter to filter out genes, this gene is included and
identified as a potential gene due to its association with Mullerian aplasia.
CNVxplorer allows to identify novel candidate genes such as HNF1B, LHX1 and GGNBP2
(Figure 3), which were described as relevant by Zhu et al. [20] aswell.
2.5 CNVxplorer permits the reproducibility of the results
CNVxplorer offers the option to download an automated generated report with the results
obtained and the information required to reproduce the analysis. In addition, the app offers an
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optional feature to include notes, patient and clinician information.
Figure 3. Example of how CNVxplorer can be used to analyze CNVs. Once the user selects
the genomic interval (chr17:34813719–36278623), two approaches are performed: approach 1
(HNF1B, GGNBP2) and approach 2 (HNF1B, LHX1).
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3
Material and Methods
3.1 CNVxplorer overview
CNVxplorer has been developed in R. The program follows a modular design that generates an
automated pipeline workflow with optional steps, such as the enrichment analysis. The code
was implemented in an interactive web application using Shiny (http//shiny.rstudio.com), an
R framework that couples the R-based statistics computation and graphics generation to the
rendering of a Web-based user interface. This technology allows the fast implementation of R
code in an easy-to-use frontend in a “reactive” environment, where the user can interact with
the data (e.g. filtering out genes through different approaches) and see the changes during the
same user session. Since the application is hosted in a remote server, the user does not need to
consume local resources and just requires a web browser to use the tool. During every session,
the parameters and data input are rested for every user. Additional materials, documentation
and FAQs will be soon available on the CNVxplorer website.
3.2 Gene-level data source
Based on HUGO Gene Nomenclature Committee (HGNC), we retrieve a list of 19,146 protein-
coding genes symbols. We set the coding boundaries of HGNC genes to Ensembl Gene 97 with
the reference human genome GRCh37.p13.
We collected genic intolerance scores of each gene from three different studies: (i) the resid-
ual variation intolerance score (RVIS) [22], (ii) loss-of-function (LoF) intolerance (gene intol-
erance score based on loss-of-function variants in 141,456 individuals), defined as pLI score,
observed/expected ratio [19] and (iii) the number of constrained coding regions (CCRs) in the
99th percentile or higher [23]. An alternative version of RVIS (ncRVIS) and GERP (ncGERP)
using proximal regulatory regions (5’UTR, 3’UTR, 250bp upstream of TSS) was used [22].
Besides, we included curated databases that classify genes according to its dosage effect:
haploinsufficieny, triplosensitivity genes [24] and a quantitative score of the haploinsufficiency
(HI index) using a predictive model based on the differences between those genes and the rest
of them [25]. We curated genes associated with developmental disorders [24] and genes whose
protein products are known to be the mechanistic targets of FDA-approved drugs [26]. In
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addition, genes associated with variants classified as likely-pathogenic or pathogenic were curated
from ClinVar [27]
Finally, we collected gene expression data of 42 tissue from the genotype-tissue Expression
Project (GTEx) [28] and protein expression of 48 tissues from Human Protein Atlas (HPA) [29]
3.3 Clinical data source
HPO terms and diseases associated with genes were obtained from Human Phenotype Ontology
(HPO) [30], Online Mendelian Inheritance in Man (OMIM) [31] and ORPHANET [32]. De-
scription of each human phenotype term is retrieved with the R package rols (v. 2.12.0). Access
to PubMed articles is performed with the R package rentrez (v.1.2.2). The query is performed
with the chromosomal bands that overlap with the genomic interval defined by the user.
3.4 Functional genomics data source
We curated associations of enhancers with target genes [33]. We filtered out predicted enhancers
and enhancer-gene associations below score 1. In total, we collected 107,168 enhancer-target
pairs. The TAD boundaries file used [34] was generated using H1 human embryonic stem cells
(hESCs), a bin size of 40kbs and a window size of 2 Mb. We curated lncRNAs data from human
with their genomic coordinates and expression profiles across 7 organs, from early organogenesis
to adulthood [35].
3.5 Sequence conservation of regulatory regions
PhastCons scores for three multi-species alignment (verterbrates, mammals and primates) were
obtained from CADD (version 1.3) [36]. Intra-species conservation score is calculated as the
ratio between the number of observed variants and the expected number of variants in a specific
genomic region. A value closer to 0 means that the region is highly conserved since the number
of variants found is much lower in comparison with the number of expected variants. Observed
variants are obtained from VCF files of gnomAD and the expected number of variants are
calculated as the sum of the expected probabilities of mutability for each nucleotide based on
its local sequence context. Expected probabilities for each triplet of nucleotides were obtained
from Supplementary Table 1 [37].
3.6 Functional analysis
Functional enrichment of annotations from the GO Consortium are performed using R package
ClusterProfiler (v. 3.12.0) [38]. For the pathway analysis, we considered two sources: KEGG [39]
and REACTOME [40]. The enrichment analysis is performed with the R packages ClusterPro-
filer [38] and reactomePA [41] respectively. Disease Ontology enrichment analysis is computed
and visualized with the R package DOSE (v. 3.10.2) [42]
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3.7 Data processing
All input features were mapped to the human reference build hg19. Since enhancer data was
originally mapped in hg38, we used Liftover chains [43] to convert it to hg19. The list of
inaccurate genomic regions, such as segmental duplications or low mappability were obtained
[44].
3.8 Clinical report
Clinical reports are generated with Rmarkdown (http://rmarkdown.rstudio.com/), a R package
to elaborate dynamic documents with R. The reports are generated automatically depending on
the data input and configurable parameters introduced by the user. The design of the document
is generated with the R package prettydoc (v 0.1.0).
3.9 Software availability
CNVxplorer will be freely accessible from a website. For a local installation, a github page with
the source code will be soon available. In order to provide easy installation, a docker-image
container with required data and code will be available for the user too.
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4
Dicussion
In summary, CNVxplorer comprises an efficient aggregation of information from human genomics
databases and the possibility of multiple functional analysis, which allow for quick overview and
assessment of candidate genes and their underlying mechanism in a genomic interval defined
by the user. OMIM provides essential information about the association of mendelian diseases
and genes. DGV and gnomAD provide a complete database of CNVs from healthy population.
Besides, gnomAD provides genic-intolerance scores which assess the potential pathogenicity.
ClinVar provides variants which are classified by their pathogenicity. GWAS Catalog provides
SNP-trait associations and their mapped genes. Clingen offers a curated list of haploinsufficiency
and triplosensitivity genes. DECIPHER provides CNVs from patients with developmental dis-
orders.
Since the identification of causal genes is a challenge due to the heterogeneity of both the
genotype and the phenotype, the user can filter genes mapped in the region based on the gene-
level information displayed. In addition, the app discards those genes identified as less relevant
from a clinical point of view. Once the most relevant genes have been selected, the user can
assess clinical features of the patient (e.g. organ(s) affected) with tissue-specific expression by
directly selecting the phenotype terms observed in the interface (e.g. Blindness, Heart defect...).
CNVxplorer will search for genes, which have been associated previously with these phenotype
terms.
Despite the actual version of the application uses diverse sources of data, a next step would
be the inclusion of more resources of clinical interest, such as: (i) Databases like NephQTL
[45] or CKDdb [46] , both based on kidney-related pathologies, that summary expression quan-
titative trait loci (eQTL) studies and provide a reliable way to assess genes and phenotypes
tissue-specific. (ii) Another source of interesting databases that can be useful are those that
describe drug-gene interactions such as DGIdb or Drugbank which would allow to infer possible
alternative treatments. (iii) Model organism databases that have demonstrated to be practical
in the interpretation of variants [14] [47], such as mouse (MGD) [48], zebrafish (ZFIN) [49] and
drosophila (FlyBase) [50]
CNVxplorer provides access to regulatory elements such as enhancers, lncRNA and TADs.
Due to the redundancy of the regulatory circuit of the genome, the assessment of causal variants
mapped in enhancers or lncRNAs with a phenotype remains a challenge. CNVxplorer displays
inter-species conservation scores in order to identify accurately those susceptible regions. Even
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though the conservation scores have been widely used in the interpretation of variants located in
mapped-regions, it has been observed that evolutionary conservation can not help much in the
prediction of disease-related enhancers, since human-specific enhancers can harbour important
functions [51]. CNVxplorer offers a complementary score based on intra-species conservation
that should facilitates the interpretation of CNVs that disrupt these regions. CNVxplorer also
gives the option to include , the target genes of enhancers that have been disrupted and are not
located in the CNV in the downstream analysis. Through these resources, our software allows
to assess the effect of regulatory regions and their target genes that are likely not included in
manual analysis or using other software tools.
CNVxplorer was conceived as a tool used in a clinical and research environment. To that
end, CNVxplorer has been developed as a quick and user-friendly tool which allows to download
and export the results obtained for further analysis in other software (e.g. Microsoft Excel), as
well as to download an automated report with the required data to replicate the analysis. These
features suppose an improvement in comparison with manual analysis based on inconsistency
and subjectivity.
Despite these advantages, our application have limitations. Since the purpose of the appli-
cation is to be implemented in a clinical and research environment, a local installation is recom-
mended. In this case, the user would have to download the source code, install the dependencies
and download the data needed to run the app. This process can hinder its implementation.
This issue can improve using software containers such as Docker which encapsulate all the re-
quirements to run the app and allow an easy installation. Another issue is the GeneHancer data
which identifies enhancers without taking into account their tissue-specificity. Some projects
[52] [53] provide tissue-specific regulatory regions, which can improve the assessment of causal
variants mapped in those regions and the clinical features of the patient.
A next step, will be to adapt our program to analyze Next Generation Sequencing (NGS)
data accepting multiple CNVs at the same time. Another possible feature, it is the development
of new techniques, such as machine learning models, that would allow a ranking of each variant
based on the gene content.
In conclusion, CNVxplorer offers a new approach to the interpretation of CNVs that provides
the opportunity to prioritize genes located in CNVs that may be causal for a specific phenotype
thus improving our knowledge of the underlying biological mechanism responsible for the disease.
The use of this application together with other tools will provide new insight into the effect of
CNVs in a clinical context.
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5
Supplementary information
5.1 Table S1: List of Human Genetics Databases
Source Description Reference
GWAS Catalog Genes associated with GWAS studies [54]
DrugBank Protein targets of FDA-approved drugs [26]
DECIPHER Unhealthy population (CNVs) [24]
OMIM Genes associated with mendelian disorders [24]
gnomAD Gene intolerance score (pLI) [19]
gnomAD Gene intolerance score (obs/exp) [19]
gnomAD Healthy population (CNVs) [19]
DGV Healthy population (CNVs) [55]
ClinVar Genes associated with human variants [27]
Clingen Haploinsufficiency genes [54]
Clingen Triplosensitivity genes [54]
GTEx Gene-expression data [28]
HPA Protein-expression data [29]
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Acronyms
• CNV: Copy Number Variant
• SNV: Single Nucleotide Variant
• TAD: Topological Associating Domain
• lncRNAs: long noncoding RNA
• GO: Gene Ontology
• HPO: Human Phenotype Ontology
• DO: Disease Ontology
• OMIM: Online Mendelian Inheritance in Man
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